Form 4: Teva Pharmaceuticals: Director Nisen Acquires Restricted Share Units

Teva Pharmaceuticals Director Perry Nisen acquired 7,242 restricted share units on May 28, 2026, as part of his compensation.

Summary

• Perry Nisen, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units (RSUs) on May 28, 2026.
• These RSUs represent a contingent right to receive one ordinary share or its cash equivalent upon settlement.
• The RSUs are scheduled to vest on May 28, 2027.
• The transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director rather than a significant strategic or financial event.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The grant of RSUs is a standard form of executive compensation, aligning management interests with shareholders.

Future Outlook

The restricted share units granted will vest on May 28, 2027, at which point they will convert into ordinary shares or their cash equivalent.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the acquisition of equity by directors, are common within the pharmaceutical industry as a method of executive compensation and a signal of management's commitment.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director is a routine compensation event and is unlikely to have a direct, immediate impact on share price, but it aligns director interests with long-term shareholder value.

Next Steps

• Vesting of restricted share units on May 28, 2027.

Key Dates

Keywords

Teva Pharmaceuticals, Form 4, SEC Filing, Director, Restricted Share Units, Equity Award, Compensation, Insider Transaction